Online inquiry

IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8907MR)

This product GTTS-WQ8907MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IGHE gene. The antibody can be applied in Chronic idiopathic urticaria research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NC_000014.9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3497
UniProt ID P01854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ8907MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2734MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG-139
GTTS-WQ5989MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 095
GTTS-WQ6558MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA D2E7
GTTS-WQ359MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ15678MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA VB6-845
GTTS-WQ5634MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP870
GTTS-WQ7458MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GBR-830
GTTS-WQ13759MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN 1500
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW